Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

NCT06779929 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 70000

Last updated 2026-05-15

No results posted yet for this study

Summary

This cohort study was initiated to emulate the design of the SURPASS-CVOT trial using observational analogues of the trial design components in a study based on insurance claims data.

Conditions

Interventions

DRUG

Tirzepatide

Tirzepatide

DRUG

Dulaglutide

Dulaglutide

DRUG

Semaglutide

Semaglutide

Sponsors & Collaborators

  • Brigham and Women's Hospital

    lead OTHER

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-01
Primary Completion
2025-12-01
Completion
2026-03-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06779929 on ClinicalTrials.gov